I Can See More Clearly Now – FDA Issues Needed Guidance on Inspection Policies During COVID-19

September 11, 2020

FDA has previously made several public statements about its ability to conduct inspections and FDA personnel have also made policy comments in various public forums. Now that this guidance has been published, we explore how to be prepared for the implementation of these policies.

Previous Flipbook
COVID-19 HEALTH AUTHORITY UPDATES 18 DECEMBER 2020
COVID-19 HEALTH AUTHORITY UPDATES 18 DECEMBER 2020

Next Article
The Special Approval Pathway (SAP) for COVID-19 related products in China
The Special Approval Pathway (SAP) for COVID-19 related products in China

Since the COVID-19 pandemic began in early 2020, the Center for Drug Evaluation (CDE) has maximized its cap...